Bio-Connect

ELISA Kit for Karyopherin Alpha 2 (KPNa2)

SEE748HU
Cloud-Clone Corp.
Product group Assays
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Cloud-Clone Corp.
  • Product Name
    ELISA Kit for Karyopherin Alpha 2 (KPNa2)
  • Delivery Days Customer
    12
  • Assay Detection Range
    125-8,000pg/mL
  • Assay Precision
    Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Karyopherin Alpha 2 (KPNa2) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle ...
  • Assay Sensitivity
    The minimum detectable dose of this kit is typically less than 55pg/mL
  • Assay Test Principle
    The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Karyopherin Alpha 2 (KPNa2). Standards or samples are then added to the appropriate ...
  • Assay Time
    3h
  • Certification
    Research Use Only
  • UNSPSC
    41116158

References

  • van der Watt PJ, Okpara MO, Wishart A, et al. Nuclear transport proteins are secreted by cancer cells and identified as potential novel cancer biomarkers. Int J Cancer. 2022,150(2):347-361. doi: 10.1002/ijc.33832
    Read this paper
  • Wang CI, Yu CJ, Huang Y, et al. Association of overexpressed karyopherin alpha 2 with poor survival and its contribution to interleukin-1β-induced matrix metalloproteinase expression in oral cancer. Head Neck. 2018,40(8):1719-1733. doi: 10.1002/hed.25145
    Read this paper
  • Huang L, Zhou Y, Cao XP, et al. KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and correlates with poor prognosis. Tumour Biol. 2017,39(6):1010428317706289. doi: 10.1177/1010428317706289
    Read this paper
  • Ma S, Zhao X. KPNA2 is a promising biomarker candidate for esophageal squamous cell carcinoma and correlates with cell proliferation. Oncol Rep. 2014,32(4):1631-7. doi: 10.3892/or.2014.3381
    Read this paper